Physician profile
Michael Epstein
NPI 1437151347
$22,586.43
in general payments reported to CMS, 2019-2025
73 companies · $3,687 in 2025
The $3,687 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,881 · 2020: $1,863 · 2021: $2,504 · 2022: $2,166 · 2023: $5,470 · 2024: $4,016 · 2025: $3,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,934 · Honoraria: $1,500 · Travel and Lodging: $1,209 · Consulting Fee: $900 · Long Term Medical Supply Or Device Loan: $881 · Education: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,933.60 |
| Honoraria | $1,500.00 |
| Travel and Lodging | $1,208.50 |
| Consulting Fee | $900.00 |
| Long Term Medical Supply Or Device Loan | $880.93 |
| Education | $749.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $2,658.95 | 2022-2023 | Monoferric |
| Janssen Biotech, INC. | $1,985.67 | 2019-2025 | Tecvayli, Darzalex, Rybrevant |
| Novartis Pharmaceuticals Corporation | $1,508.32 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,107.81 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $1,087.03 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Caris Mpi, INC. | $1,052.62 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $891.12 | 2019-2025 | |
| Amgen INC. | $872.18 | 2019-2023 | Lumakras, Nplate, Vectibix |
| Genentech USA, INC. | $842.45 | 2019-2025 | Phesgo, Polivy, Lunsumio |
| Astrazeneca Pharmaceuticals Lp | $841.21 | 2019-2025 | Enhertu, Lynparza |
| Daiichi Sankyo INC. | $658.88 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Gilead Sciences, INC. | $577.55 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $541.51 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $513.84 | 2019-2025 | Fruzaqla, Iclusig, Alunbrig |
| Aveo Pharmaceuticals, INC. | $506.95 | 2022-2025 |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $466.67 | 2019-2023 | Imbruvica, Epkinly |
| Beigene, Ltd. | $450.00 | 2020 | |
| Abbvie INC. | $431.82 | 2019-2025 | |
| Exelixis INC. | $430.87 | 2019-2025 | Cabometyx |
| Celgene Corporation | $392.69 | 2019-2025 | Pomalyst, Reblozyl, Opdualag |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Glaxosmithkline, LLC. | $326.20 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Regeneron Healthcare Solutions, INC. | $302.33 | 2021-2025 | Libtayo |
| Eisai INC. | $264.00 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $254.73 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $230.92 | 2022-2024 | Ultomiris |
| Array Biopharma INC | $204.23 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Incyte Corporation | $194.39 | 2020-2025 | Jakafi, Monjuvi |
| Rigel Pharmaceuticals, INC. | $188.82 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Sanofi-Aventis U.S. LLC | $160.13 | 2019-2023 | |
| Seagen INC. | $142.61 | 2019-2023 | Adcetris |
| Dova Pharmaceuticals | $135.27 | 2020 | |
| Sanofi US Services INC. | $129.30 | 2025 | |
| Verastem, INC. | $119.85 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.38 | 2020-2025 | |
| Ge Healthcare | $104.30 | 2021-2022 | |
| Comsort, INC | $100.00 | 2019 | |
| Lilly USA, LLC | $94.55 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Sobi, INC | $87.61 | 2022-2024 | |
| Beigene USA, INC. | $86.08 | 2020-2025 | Brukinsa, Tevimbra |
| Qol Medical, LLC | $75.29 | 2022-2023 | Sucraid |
| Emd Serono, INC. | $73.18 | 2023-2025 | Bavencio |
| Janssen Pharmaceuticals, INC | $65.02 | 2020-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.98 | 2020-2022 | |
| Adaptive Biotechnologies Corporation | $62.22 | 2024-2025 | Clonoseq |
| Pharmaessentia USA Corporation | $58.06 | 2022-2025 | Besremi |
| Morphosys, US INC. | $56.83 | 2021-2023 | Monjuvi |
| Kite Pharma, INC. | $53.86 | 2021 | |
| Stemline Therapeutics INC. | $51.28 | 2023-2024 | Orserdu |
| Syndax Pharmaceuticals, INC. | $46.06 | 2025 | |
| Janssen Scientific Affairs, LLC | $45.38 | 2019-2024 | Rybrevant |
| Cti Biopharma Corp. | $45.24 | 2022-2023 | Vonjo |
| Ipsen Biopharmaceuticals, INC | $37.15 | 2020-2022 | |
| Taiho Oncology, INC. | $33.57 | 2021-2023 | |
| Astellas Pharma US INC | $33.45 | 2023-2025 | Vyloy, Xospata |
| Deciphera Pharmaceuticals INC. | $33.08 | 2022-2024 | Qinlock |
| Tersera Therapeutics LLC | $32.88 | 2022-2023 | Zoladex |
| G1 Therapeutics, INC. | $30.10 | 2022-2023 | Cosela |
| Foundation Medicine, INC. | $26.87 | 2023 | Foundationone Liquid Cdx |
| Adc Therapeutics America, INC. | $23.54 | 2023 | |
| Puma Biotechnology, INC. | $21.83 | 2025 | |
| Epizyme, INC. | $21.62 | 2020 | |
| Geron Corporation | $20.75 | 2025 | Rytelo |
| Clovis Oncology, INC. | $20.19 | 2019-2020 | |
| Aadi Bioscience, INC. | $19.17 | 2023 | Fyarro |
| Acrotech Biopharma INC. | $18.39 | 2024 | Beleodaq |
| Spectrum Pharmaceuticals INC. | $17.63 | 2023 | Rolvedon |
| Beone Medicines USA, INC. | $16.55 | 2025 | Brukinsa |
| Immunocore Limited | $16.43 | 2025 | Kimmtrak |
| Alnylam Pharmaceuticals INC. | $15.70 | 2023 | Givlaari |
| Progenics Pharmaceuticals, INC. | $15.60 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $14.08 | 2019 | |
| Karyopharm Therapeutics INC. | $13.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.